[HTML][HTML] Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
Anti‑vascular endothelial growth factor (anti‑VEGF) agents including Bevacizumab,
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …
Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns.
A Kumar, D Agarwal - Indian Journal of Ophthalmology, 2021 - europepmc.org
Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
[PDF][PDF] Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
A Kumar, D Agarwal, A Kumar - researchgate.net
Anti‑vascular endothelial growth factor (anti‑VEGF) agents including Bevacizumab,
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …
[引用][C] Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
A Kumar, D Agarwal, A Kumar - Indian journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
[HTML][HTML] Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
A Kumar, D Agarwal, A Kumar - Indian Journal of Ophthalmology, 2021 - ncbi.nlm.nih.gov
Anti‑vascular endothelial growth factor (anti‑VEGF) agents including Bevacizumab,
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …
[PDF][PDF] Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
A Kumar, D Agarwal, A Kumar - scienceopen.com
Anti‑vascular endothelial growth factor (anti‑VEGF) agents including Bevacizumab,
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …
Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns.
A Kumar, D Agarwal - Indian Journal of Ophthalmology, 2021 - europepmc.org
Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …